Member Info for Matador78

Someone snapshot the apology from Doggo.

It's going above my desk

Maybe those sells are being set aside for a buyer.

Who knows?

About SPA

Headquartered in Alexandria, Virginia, Systems Planning and Analysis, Inc. provides timely and objective analysis and integrated technical, operational, programmatic, policy, and business solutions in support of important national objectives. Our employees have expertise in an array of domains including: Air, Surface, and Undersea Warfare and Operations, Nuclear Deterrence, Safety, and Security, Radar and Sensor Systems, Ballistic Missile Systems, Integrated Air and Missile Defense, Intelligence, Surveillance, and Reconnaissance Systems, Space Systems, Improvised Threats and Analytic Software Development. To learn more about SPA, please visit www.spa.com.

About Factom, Inc.
Factom, Inc. is an Austin-based blockchain technology company that is on a mission to provide blockchain data provenance for complex industries. Factom specializes in building scalable blockchain technology to handle complex enterprise data and volume. Factom is the recognized leader in providing blockchain solutions in order to preserve, ensure and validate digital assets. For information, please visit factom.com.

https://www.finanzen.net/nachricht/aktien/spa-factom-team-up-with-blockchain-7104492

GSK and Merck KGaA, Darmstadt, Germany announce global alliance to jointly develop and commercialise M7824, a novel immunotherapy with potential in multiple difficult-to-treat cancers





· Eight high priority immuno-oncology clinical development studies ongoing or expected to commence in 2019, including studies in non-small cell lung and biliary tract cancers

· Merck KGaA, Darmstadt, Germany will receive an upfront payment of €300 million (£260 million) and is eligible for potential development milestone payments of up to €500 million (£440 million) triggered by data from the M7824 lung cancer programme, plus future approval and commercial milestones of up to €2.9 billion (£2.5 billion), for a total potential deal value of up to €3.7 billion (£3.2 billion)

GSK and Merck KGaA, Darmstadt, Germany announce global alliance to jointly develop and commercialise M7824, a novel immunotherapy with potential in multiple difficult-to-treat cancers





· Eight high priority immuno-oncology clinical development studies ongoing or expected to commence in 2019, including studies in non-small cell lung and biliary tract cancers

· Merck KGaA, Darmstadt, Germany will receive an upfront payment of €300 million (£260 million) and is eligible for potential development milestone payments of up to €500 million (£440 million) triggered by data from the M7824 lung cancer programme, plus future approval and commercial milestones of up to €2.9 billion (£2.5 billion), for a total potential deal value of up to €3.7 billion (£3.2 billion)

https://medium.com/@DJohnstonEC/decentralizing-growth-capital-part-1-1f15c692642

The other side of this market is incredible. Enterprises have heard about blockchain. Goldman Sachs, IBM, Fidelity, NYSE have made major announcements already and have set aside large budgets. Many more are coming. Others are very skeptical. And with good reason. Enterprise change is hard, and doubly hard when new technology means changing more than just code. Blockchain projects often disturb existing business practices, monetization models, core efficiencies, and other sacred cows. This requires broad buy-in from executives. And much like the internet itself, there are executives who believe blockchain is a fad, that it will go away. We know differently, don’t we?

https://apnews.com/ba12ee8a3fae4ee08d5483d96a0fb5f4

Call him up and ask him O'donnell

All kicking off

https://www.eurekalert.org/pub_releases/2019-02/imi-lvf020119.php

Monday, February 4th, London, UK - Recent breakthroughs in diagnostics and therapeutics of age-related diseases and aging itself lead to the emergence of the longevity biotechnology industry with a number of credible companies and exponential business models. To accelerate this emerging trend a team of professional investors and biotechnology entrepreneurs created the Longevity Vision Fund, a new venture capital fund focused on early-stage technologies and life-science businesses. The Fund seeks to invest in companies that provide products, services, and technologies aimed to extend the period of healthy human life.

"The Fund's mission is to lead the breakthrough in human longevity and to extend human lifespan worldwide allowing people to live longer, healthier lives", - said Sergey Young, the Founder of Longevity Vision Fund.

http://usindustrynews.com/10742/global-blockchain-identity-management-market-outlook-2018-2025-keyplayers-aws-ibm-civic-technologies-bitfury-kyc-chain-factom-oracle-evernym/

https://www.news-medical.net/news/20190201/Insilico-to-present-its-latest-results-in-AI-for-Drug-Discovery-on-CXOTalk-Show.aspx

Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for Drug Discovery on a live episode of the influential CXOTalk Show on February 8, 2019 at 1:00 PM Eastern time.

Artificial intelligence (AI) has the potential to transform the pharmaceutical industry, making the hunt for new pharmaceuticals quicker and more effective. With AI comes the potential to improve drug approval rates, reduce development costs, get medications to patients faster and help patients comply with their treatments.

Both sound like the type of bands Doggo goes to see

https://www.businesswire.com/news/home/20190204005265/en/Juvenescence-Buck-Institute-Launch-New-Company-Develop

BHB Therapeutics

DOUGLAS, Isle of Man--(BUSINESS WIRE)--Juvenescence, a biopharmaceutical development company focused on therapeutics for aging, and the Buck Institute for Research on Aging announce a new collaboration with the formation of BHB Therapeutics, Ltd, a joint venture. The company will focus on novel approaches to inducing a state of ketosis, which may have protective effects against age-related disease.

Juvenescence and the Buck institute have just launched a new company.

First person to tell me what it is get's a set of new windows from Wadnob

https://www.hilldickinson.com/insights/articles/global-medicinal-cannabis-market-gains-momentum

The firm advises a number of larger established North American integrated companies, UK and European focused start-ups and joint ventures, as well as regulated institutions advising or raising capital for projects in the industry.

Our experience includes:

•advising FastForward Innovations Limited (AIM:FFWD) on the first medical cannabis investment by a UK-listed company since GW Pharma
•listing Sativa Investments Plc on the NEX Growth Market, the first listing of a medical cannabis-focused company in the UK since 1998

The analysts at the institution I work think "it will be 3-5 years before mainstream production environments are taken for granted,".

Trick is to get in very very early

https://www.news-medical.net/news/20190201/Insilico-to-present-its-latest-results-in-AI-for-Drug-Discovery-on-CXOTalk-Show.aspx

Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for Drug Discovery on a live episode of the influential CXOTalk Show on February 8, 2019 at 1:00 PM Eastern time.

Artificial intelligence (AI) has the potential to transform the pharmaceutical industry, making the hunt for new pharmaceuticals quicker and more effective. With AI comes the potential to improve drug approval rates, reduce development costs, get medications to patients faster and help patients comply with their treatments.

I meant official source, I cant access the who website from work due to them blocking anything regarding cannabis.

http://www.voxy.co.nz/business/5/331189

I'm struggling to find any decent sources for this. anyone else find anything?